Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 16/20 | 0.72 |
| ▸ | UBA3 | Q8TBC4 | 16/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL805414 | 0.93 | NAE1 (0.64) | NAE1UBA3CHRM4CHRM2CHRM5 | |
| SCHEMBL783611 | 0.83 | NAE1 (1.00) | NAE1UBA3 | |
| SCHEMBL783729 | 0.78 | NAE1 (0.88) | NAE1UBA3CHRM4 | |
| SCHEMBL19185666 | 0.74 | NAE1 (0.73) | NAE1UBA3 | |
| SCHEMBL12452302 | 0.74 | NAE1 (0.61) | NAE1UBA3 | |
| SCHEMBL10283376 | 0.74 | NAE1 (0.44) | NAE1UBA3 | |
| SCHEMBL10283822 | 0.73 | NAE1 (0.53) | NAE1UBA3 | |
| SCHEMBL805370 | 0.71 | NAE1 (0.79) | NAE1UBA3 | |
| SCHEMBL12453644 | 0.70 | NAE1 (0.80) | NAE1UBA3 | |
| SCHEMBL805389 | 0.65 | NAE1 (0.73) | NAE1UBA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071482-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885CHRM4 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.